Trial Profile
A Multiple-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and QTc Effect of MK-8189 in Participants With Schizophrenia and Healthy Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs MK 8189 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Acronyms MDCS
- Sponsors Merck Sharp & Dohme
- 15 Apr 2020 Status changed from active, no longer recruiting to completed.
- 25 Feb 2020 Planned End Date changed from 11 Mar 2020 to 27 Mar 2020.
- 25 Feb 2020 Planned primary completion date changed from 11 Mar 2020 to 27 Mar 2020.